Healthcare Costs and Resource Utilization in Aimovig Migraine Patients: a Retrospective Study Using United States Claims Data

Completed

Conditions studied: Migraine

In brief

The proposed study is a retrospective, non-interventional analysis that uses medical and pharmacy claims data in the US from Komodo Health

Key facts

Study ID

NCT05177406

Run by

Novartis Pharmaceuticals

People needed

1839

Starts

2020-08-31

Expected to finish

2020-12-31

Last updated by the study team

2022-01-04

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• General Cohort
• Adult (18 years or older)
• Newly initiating on Aimovig (no other claims during a 180-day wash-in period)
• Had continuous medical and pharmacy benefit eligibility from 180 days pre-index of Aimovig through 180-days post-index
• Primary \& Secondary Objectives Sub-Cohort
• Had 3 consecutive months with a claim for Aimovig (≤15 days gap between days supply and the subsequent claim to be considered consecutive)
• Primary \& Secondary Objectives Cost Sensitivity Analyses Sub-Cohorts
• Had continuous medical and pharmacy benefit eligibility from 180 days pre-index of Aimovig through 270-days post-index to permit assessment of cost outcomes (all-cause and migraine-related) during days 91-270 post-index
• Had continuous medical and pharmacy benefit eligibility from 180 days pre-index of Aimovig to the maximum follow-up time post-index with continuous medical and prescription insurance eligibility until the data end date (September 1, 2019)

You may not qualify if…

• Patients with any claim for another CGRP-targeted medication (Ajovy or Emgality) during entire study period

Where it is running

• Novartis Investigative Site — East Hanover, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.